Sign In
Buy VKTX
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
Why you Should Buy the 200-day Dip in ARM, MSTR, VKTX
07:16pm, Monday, 09'th Sep 2024
The 200-day moving average can provide some of the best long-term entry points. MicroStrategy, Coinbase, and Viking Therapeutics offer high reward-to-risk as they retreat to an important technical lev
Viking Therapeutics, Inc. (VKTX) Laps the Stock Market: Here's Why
06:51pm, Monday, 09'th Sep 2024
Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $54.78, signifying a +1.2% move from its prior day's close.
3 Crazy Stocks to Buy That Are Outperforming Nvidia in 2024
07:43am, Sunday, 08'th Sep 2024
The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence that propelled Nvidia (NASDAQ:NVDA) to the forefront of the industry.
Billionaires Are Buying Viking Therapeutics Stock Left and Right. Should You Follow Their Lead?
04:26am, Saturday, 07'th Sep 2024
Viking Therapeutics is developing a weight management treatment candidate that is similar to Eli Lilly's Zepbound. Analysts' estimates for Viking Therapeutics point to huge gains for the stock over th
Prediction: This Biotech Stock Will Outperform Nvidia in the Second Half of the Year
06:05am, Thursday, 05'th Sep 2024
This stock already beat Nvidia's performance in the first half. This player operates in a market that could reach $100 billion by the end of the decade.
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
06:55pm, Wednesday, 04'th Sep 2024
Viking Therapeutics, Inc. (VKTX) reachead $58.10 at the closing of the latest trading day, reflecting a -0.5% change compared to its last close.
Viking Surges 342% in the Past Year: How Should You Play the Stock?
10:46am, Tuesday, 03'rd Sep 2024
VKTX stock continues to generate phenomenal returns, driven by encouraging development of its obesity and NASH drugs, which are nearing late-stage development.
The Best Biotech Stock to Invest $1,000 in Right Now
09:45am, Tuesday, 03'rd Sep 2024
Viking Therapeutics is developing medicines to fight obesity -- a hot area now. Its lead program appears to work better than blockbuster drugs made by others.
Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape
06:32am, Friday, 30'th Aug 2024
Viking Therapeutics' VK2735, a dual GLP-1/GIP receptor agonist, shows promising results in Phase II trials for obesity treatment with potential for both subcutaneous and oral formulations. Despite com
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
01:19pm, Thursday, 29'th Aug 2024
The weight-loss drugs market could be worth up to $144 billion within six years. And a bevy of pharma stocks could get a lift.
Viking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference
04:03pm, Wednesday, 28'th Aug 2024
SAN DIEGO , Aug. 28, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic a
Why Viking Therapeutics Stock Price Moved Down 6% on Tuesday
12:50pm, Wednesday, 28'th Aug 2024
VKTX's shares fell after rival Eli Lilly announced that it is launching cheaper versions of Zepbound to strengthen its presence in the obesity market.
Why Viking Therapeutics Stock Got Thrashed on Tuesday
06:42pm, Tuesday, 27'th Aug 2024
A very competitive peer has launched a discount offering in a white-hot corner of the pharmaceutical market. Viking is still in development with its own drug in the category.
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
10:31am, Tuesday, 27'th Aug 2024
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy
Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say
12:00pm, Monday, 26'th Aug 2024
While Eli Lilly & Co. and Novo Nordisk dominate the obesity-drug market, there's a vast field of would-be competitors closing in behind them — and the most successful among those next-wave contender
